A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Clinical trial NCT07291076 · RECRUITING
Trial details
- NCT number
- NCT07291076
- Sponsor
- Bristol-Myers Squibb
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-16
- Primary completion
- 2029-10-15
- Enrollment
- 198
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.